Skip to search form
Skip to main content
Semantic Scholar's Logo
Create Free Account
You are currently offline. Some features of the site may not work correctly.
, 3-((1-diethylaminoethylidene)azinomethyl)rifamycin SV
A semisynthetic derivative of rifamycin with a longer biological half-life than rifampicin.
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species.
N. D. Cooverj
Corpus ID: 33743571
Single and repeated dose experiments in mice, rats, dogs and monkeys are reported in this study to assess the pharmacokinetics…
Phase I Pharmacokinetic Study of a New 3-Azinomethyl-Rifamycin (Rifametane) as Compared to Rifampicin
Corpus ID: 43477999
An open randomized cross-over study was conducted in 8 healthy male volunteers to study the pharmacokinetic pattern and the…
Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
International journal of clinical pharmacology…
Corpus ID: 36931357
The pharmacokinetics and tolerance of a single oral dose (150 mg) of a new 3-azinomethyl rifamycin (SPA-S-565, USAN rifametane…
The antibacterial activity of a new 3-azinomethyl-rifamycin.
Il Farmaco; edizione scientifica
Corpus ID: 8360899
The new 3-azinomethyl-rifamycin, SPA-S-565, was shown to exert an effective antibacterial activity in vitro comparable to that of…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE